Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Reform in the Balance: What It Means for Biopharma

This article was originally published in RPM Report

Executive Summary

The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach.

You may also be interested in...



Defining Line Extensions: Medicaid Rebate Change Gives CMS Power to take a Bite Out of Lifecycle Management

A new provision in the health care reform law means that new formulations of oral brand name drugs will be subject to additional rebates. But who is affected depends in part on how CMS defines a line extension.

Health Care Reform and the Biopharma Sector: A Complete Tactical Victory

The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?

Defining Line Extensions: Medicaid Rebate Change Gives CMS Power to take a Bite Out of Lifecycle Management

A new provision in the health care reform law means that new formulations of oral brand name drugs will be subject to additional rebates. But who is affected depends in part on how CMS defines a line extension.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS080638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel